Barings LLC purchased a new position in shares of Qiagen NV (NASDAQ:QGEN) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 8,100 shares of the company’s stock, valued at approximately $255,000.
Several other hedge funds also recently modified their holdings of QGEN. BlackRock Inc. raised its stake in Qiagen by 4.6% during the second quarter. BlackRock Inc. now owns 8,203,013 shares of the company’s stock worth $275,048,000 after acquiring an additional 363,377 shares during the period. Vanguard Group Inc. raised its stake in Qiagen by 7.0% during the second quarter. Vanguard Group Inc. now owns 6,053,863 shares of the company’s stock worth $202,986,000 after acquiring an additional 394,201 shares during the period. Frontier Capital Management Co. LLC raised its stake in Qiagen by 0.7% during the third quarter. Frontier Capital Management Co. LLC now owns 2,554,021 shares of the company’s stock worth $80,452,000 after acquiring an additional 17,946 shares during the period. State Street Corp raised its stake in Qiagen by 2.1% during the second quarter. State Street Corp now owns 2,330,061 shares of the company’s stock worth $78,130,000 after acquiring an additional 48,679 shares during the period. Finally, Legal & General Group Plc raised its stake in Qiagen by 0.8% during the third quarter. Legal & General Group Plc now owns 1,909,956 shares of the company’s stock worth $52,573,000 after acquiring an additional 15,660 shares during the period. 62.24% of the stock is currently owned by institutional investors and hedge funds.
Shares of Qiagen NV (QGEN) traded down $0.16 during trading hours on Friday, hitting $30.93. 661,484 shares of the company’s stock traded hands, compared to its average volume of 830,046. Qiagen NV has a 12 month low of $27.51 and a 12 month high of $36.34. The firm has a market capitalization of $7,140.00, a price-to-earnings ratio of 79.31, a P/E/G ratio of 1.90 and a beta of 1.10. The company has a quick ratio of 4.78, a current ratio of 5.33 and a debt-to-equity ratio of 0.68.
Several equities research analysts recently weighed in on the stock. TheStreet upgraded shares of Qiagen from a “c+” rating to a “b+” rating in a research note on Tuesday, November 7th. Zacks Investment Research lowered shares of Qiagen from a “buy” rating to a “hold” rating in a research note on Monday, October 16th. Cowen reiterated a “hold” rating and set a $34.00 price objective on shares of Qiagen in a research note on Thursday, December 21st. Deutsche Bank restated a “buy” rating on shares of Qiagen in a research note on Wednesday, November 8th. Finally, Commerzbank restated a “buy” rating on shares of Qiagen in a research note on Tuesday, December 12th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and five have given a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $34.19.
TRADEMARK VIOLATION WARNING: “Barings LLC Acquires Shares of 8,100 Qiagen NV (NASDAQ:QGEN)” was first published by Week Herald and is owned by of Week Herald. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright law. The correct version of this piece of content can be accessed at https://weekherald.com/2017/12/30/barings-llc-acquires-shares-of-8100-qiagen-n-v-qgen.html.
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.